Product Name: CellCept [mycophenolate mofetil]
Date of Report: 1/26/2005
Phase: III
Two-arm, open-label, randomized, multi-center study of the addition of CellCept (MMF, mycophenolate mofetil) to a tacrolimus-based immunosuppressive regimen for the prevention of acute rejection in hepatic allografts recipients.
Product Name: CellCept [mycophenolate mofetil]
Date of Report: 7/1/2005
Phase: IV
Open-label, comparative study of daclizumab in combination with mycophenolate mofetil and tacrolimus versus tacrolimus in combination with steroids for the prevention of acute rejection in recipients of allogenic liver transplants.
Product Name: CellCept [mycophenolate mofetil]
Date of Report: To be Published
Phase: IV
A prospective, open-label, multi-center, randomized trial of the efficacy and safety of a long term calcineurin inhibitor free maintenance regimen with mycophenolate mofetil and sirolimus in recipients of an orthotopic liver transplant
Product Name: CellCept [mycophenolate mofetil]
Date of Report: 12/1/2005
Phase: IV
A study of the safety, tolerability and pharmacokinetics of oral CellCept (mycophenolate mofetil, MMF) in pediatric liver transplant recipients on concomitant treatment with Cyclosporine and Corticosteroids.
Product Name: CellCept [mycophenolate mofetil]
Date of Report: 6/12/2006
Phase: II
An Exploratory Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Tolerability of Mycophenolate Mofetil (CellCept) in Liver Transplant Patients Receiving Standard or Reduced Levels of Tacrolimus (Prograf).
Product Name: CellCept [mycophenolate mofetil]
Date of Report: To be Published
Phase: IV
A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Liver Transplant Patients.
Product Name: CellCept [mycophenolate mofetil]
Date of Report: To be Published
Phase: IV
A Study of CellCept (Mycophenolate Mofetil) Combined WIth Calcineurin Inhibitors in Liver Transplant Patients.
Product Name: Zenapax [daclizumab]
Date of Report: To be Published
Phase: III
(Elite ReSpECT study) A Study of Zenapax (daclizumab) in Patients who have Undergone Liver Transplantation
Product Name: Zenapax [daclizumab]
Date of Report: 7/15/2005
Phase: III
Evaluation of renal function in liver transplant recipients receiving dacilizumab (Zenapax) and mycophenolate mofetil (CellCept, MMF) and a delayed lower dose of tacrolimus vs a standard dose tacrolimus-based regimen.
